Parkinson’s disease Archives
Jun. 29, 2018—Analysis of data from a clinical trial conducted at Vanderbilt suggests that deep brain stimulation (DBS) administered to patients with very early-stage Parkinson’s disease slowed the progression of rest tremor. The study, published June 29 in Neurology, is significant because it is the first evidence of a treatment that may possibly delay the progression of...
Jan. 18, 2018—Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
Sep. 1, 2016—A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.
Oct. 22, 2015—Despite benefiting from dramatic improvements in movement after deep brain stimulation surgery, patients with Parkinson’s disease can be inadequately served when physicians and researchers focus only on its motor manifestations, says a Vanderbilt neurosurgeon.
Feb. 19, 2015—Mitochondria not only are the cell’s main power producers, they are also the chief cooks and bottle washers.
Aug. 14, 2014—Reporting last week in the journal Cell, researchers from Oregon Health and Science University, Harvard Medical School and Vanderbilt University describe the first “four-dimensional” picture of a brain receptor that plays a key role in learning and memory.
Apr. 3, 2014—A long-term Vanderbilt University Medical Center study of deep brain stimulation (DBS) in early-stage Parkinson’s disease has received approval from the Food and Drug Administration (FDA) to continue in a pivotal, phase III, large-scale safety and efficacy trial.
Mar. 13, 2014—Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.